Insulet Corporation (NASDAQ:PODD) is one of the 8 Most Oversold Strong Buy-Rated Stocks to Invest In.
On March 30, 2026, Insulet Corporation (NASDAQ:PODD) announced the appointment of Mike Panos as Executive Vice President and Chief Commercial Officer, effective immediately. Mike Panos will lead the company’s global commercial organization and report to President and Chief Executive Officer Ashley McEvoy, while also joining the Executive Leadership Team. Mike Panos brings 30 years of commercial leadership experience in medical technology, most recently serving as Leader, Sales Excellence at Stryker Corporation.
On March 13, 2026, Truist said shares of Insulet were trading lower following an 8-K disclosure of a Voluntary Device Correction for certain Omnipod 5 lots. Truist noted the issue could serve as a negative headline amid increasing competition, but said the impact should be manageable, citing 18 reported serious adverse events with no deaths and no change to guidance. Truist added that remediation costs will be excluded from non-GAAP results and maintained a Buy rating with a price target, while noting the stock reaction appears worse than the likely financial or market share impact.
Cherries/Shutterstock.com
Earlier in March, Insulet presented new clinical data supporting the development of its fully closed-loop automated insulin delivery system for type 2 diabetes at the ATTD conference in Barcelona. The EVOLUTION 2C feasibility study included 24 participants and showed time in range increased to 68%, a 24% improvement over standard injection therapy, with time below range at 0.14%. The study reported no severe hypoglycemia or diabetic ketoacidosis events, with improved glycemic outcomes observed across a diverse participant group.
Insulet Corporation (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
While we acknowledge the potential of PODD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
Leave a Reply